<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl10" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>KHM-3S cells</th><th>pEGFR</th><th>pAKT</th><th>pERK</th><th>pMET</th></tr></thead><tbody><tr><td>Control</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Erlotinib alone</td><td>0.008</td><td>0.609</td><td>0.18</td><td>1.098</td></tr><tr><td>Erlotinib + HGF</td><td>0.014</td><td>1.381</td><td>0.979</td><td>11.66</td></tr><tr><td>Erlotinib + HGF + Crizotinib</td><td>0.023</td><td>0.417</td><td>0.085</td><td>1.095</td></tr></tbody></table><table-wrap-foot><fn><p>&#8226; HGF activates pMET and pERK in the presence of Erlotinib.</p></fn><fn><p>&#8226; Crizotinib blocks HGF-induced pMET and pERK activation.</p></fn></table-wrap-foot></table-wrap>